Latest Avastin Stories
INCLINE VILLAGE, Nev., Dec. 1, 2010 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
NEW YORK, LONDON and BERMUDA, Oct. 21 /PRNewswire/ -- Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today announced that the U.S. Patent Office has issued U.S. patent 7,816,323, for novel methods to treat breast and colon cancers using a combination therapy of XereceptÂ® with AvastinÂ®.
Age-related macular degeneration (AMD) is the leading cause of blindness for people over fifty.
Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
INCLINE VILLAGE, Nev., Sept. 1 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
Federal health scientists said Friday that follow-up studies of a Roche breast cancer drug showed it failed to slow tumor growth or extend patient lives.
LONDON, May 3, 2010 /PRNewswire/ -- The rheumatoid arthritis treatment Humira will replace Lipitor as the world's biggest-selling drug in 2016, but a familiar name, Pfizer, will still be the biggest seller of medicines after the patent cliff according to the World Preview 2016 report published today by EvaluatePharma, the premier provider of pharma and biotech analysis. The cancer treatment Avastin had been widely expected to emerge as the biggest blockbuster drug following patent expiry...
NEW YORK, LONDON and BERMUDA, April 19, 2010 /PRNewswire/ -- Celtic Pharmaceutical Holdings L.P.
NEW YORK, Jan. 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
- A hairdresser.